Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 USD | -6.04% | +11.11% | +12.90% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
Business Summary
Number of employees: 167
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 292 | 100.0 % | 195 | 100.0 % | -33.46% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 292 | 100.0 % | 195 | 100.0 % | -33.46% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 13-06-30 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 22-03-31 |
Michel Dahan
COO | Chief Operating Officer | 45 | 12-12-31 |
Steven Burke
CTO | Chief Tech/Sci/R&D Officer | 63 | 19-06-16 |
Chief Tech/Sci/R&D Officer | - | - | |
Corporate Officer/Principal | - | - | |
Carolyn Rucci
LAW | General Counsel | - | 20-12-31 |
Meredith Bowman
HRO | Human Resources Officer | - | 22-04-30 |
Christian Barnes
PRN | Corporate Officer/Principal | - | - |
Nicholas Grund
PRN | Corporate Officer/Principal | 54 | Jan. 08 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 18-12-11 |
Adrian Adams
CHM | Chairman | 73 | 18-12-11 |
Director/Board Member | 65 | 21-02-15 | |
John Butler
CEO | Chief Executive Officer | 59 | 13-06-30 |
Steven Gilman
BRD | Director/Board Member | 71 | 18-12-11 |
Ronald Frieson
BRD | Director/Board Member | 65 | 21-10-31 |
Cynthia Smith
BRD | Director/Board Member | 55 | 18-08-27 |
Myles Wolf
BRD | Director/Board Member | 53 | 20-04-05 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 209,595,254 | 189,336,406 ( 90.33 %) | 0 | 90.33 % |
Company contact information
Akebia Therapeutics, Inc.
245 First Street Suite 1400
02142, Cambridge
+617 871 2098
http://www.akebia.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.90% | 293M | |
+10.44% | 107B | |
+0.82% | 106B | |
+6.72% | 23.47B | |
-13.89% | 21.9B | |
-6.64% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- AKBA Stock
- Company Akebia Therapeutics, Inc.